IMPORTANT INVESTIGATION UPDATE: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/02/24
IMPORTANT INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 06/01/24
IMPORTANT INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/31/24
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/30/24
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/19/24
IMPORTANT SHAREHOLDER INVESTIGATION: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/17/24
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/16/24
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 05/15/24
ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial ResultsGlobeNewsWire • 05/09/24
ARS Pharmaceuticals Submits Response for neffy® (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New ZealandGlobeNewsWire • 04/30/24
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against ARS Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the FirmAccesswire • 04/08/24
ARS Pharmaceuticals Submits Response to FDA Complete Response Letter for neffy® (Epinephrine Nasal Spray)GlobeNewsWire • 04/03/24
ARS Pharmaceuticals, Inc. (SPRY) Upgraded to Buy: Here's What You Should KnowZacks Investment Research • 04/01/24
Recent Price Trend in ARS Pharmaceuticals, Inc. (SPRY) is Your Friend, Here's WhyZacks Investment Research • 03/26/24
SPRY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by ARS Pharmaceuticals, Inc.Accesswire • 03/26/24
ATTENTION ARS Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your RightsAccesswire • 03/25/24
Investors who lost money on ARS Pharmaceuticals, Inc. should contact Levi & Korsinsky about an ongoing investigation - SPRYAccesswire • 03/22/24
ARS Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewsWire • 03/21/24
ARS Pharmaceuticals, Inc. Investigated Regarding Potential Securities Law Violations - Contact Levi & Korsinsky for Details- SPRYAccesswire • 03/21/24
ATTENTION ARS Pharmaceuticals, Inc. Investors: You May Have Been Affected by Fraud - Contact Levi & Korsinsky to Discuss Your RightsAccesswire • 03/20/24
An Investigation Has Commenced on Behalf of ARS Pharmaceuticals, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your SPRY Losses.Accesswire • 03/19/24
Wall Street Favorites: 3 Under-$10 Stocks with Strong Buy Ratings for March 2024InvestorPlace • 03/15/24
Did ARS Pharmaceuticals, Inc. Mislead Investors? Shareholder Rights Advocates at Levi & Korsinsky Investigate - SPRYAccesswire • 03/14/24
